{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:33:52Z","timestamp":1790836432848,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.clinthera.2006.01.015","type":"journal-article","created":{"date-parts":[[2006,2,19]],"date-time":"2006-02-19T07:15:17Z","timestamp":1140333317000},"page":"55-72","source":"Crossref","is-referenced-by-count":228,"title":["Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers"],"prefix":"10.1016","volume":"28","author":[{"given":"Arthur J.","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanYan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"De Smet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Winchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ramael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.01.015_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11892-003-0079-9","article-title":"Gut peptides and type 2 diabetes mellitus treatment","volume":"3","author":"Ahren","year":"2003","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2006.01.015_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.12.1.87","article-title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","volume":"12","author":"Drucker","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2006.01.015_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1381612013397401","article-title":"Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes","volume":"7","author":"Drucker","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2006.01.015_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.regpep.2004.06.007","article-title":"What do we know about the secretion and degradation of incretin hormones?","volume":"128","author":"Deacon","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.clinthera.2006.01.015_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.01.015_bib7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a4-week study period in type 2 diabetes","volume":"25","author":"Ahren","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib8","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral anti hyperglycemic therapy for type 2 diabetes: Scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.01.015_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","article-title":"Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats","volume":"52","author":"Pospisilik","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1530\/eje.0.1460717","article-title":"Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice","volume":"146","author":"Reimer","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2006.01.015_bib12","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib13","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effect of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.01.015_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoro-methyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orallyactive dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2006.01.015_bib17","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamicsofsitagliptin, an inhibitor of dipep-tidyl peptidase IV, in healthy subjects: Results from tworandomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.01.015_bib19","doi-asserted-by":"crossref","first-page":"22418","DOI":"10.1074\/jbc.M212355200","article-title":"The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase activatingpolypeptide-(1\u201338)","volume":"278","author":"Zhu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2006.01.015_bib20","series-title":"Guideline for Good Clinical Practice [EMEA Web site]","author":"European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation- World Health Organization","year":"2002"},{"key":"10.1016\/j.clinthera.2006.01.015_bib21","series-title":"Recommendations Guiding Medical Doctors in Bio medical Research Involving Human Subjects [WMA Web site]","author":"World Medical Association Declaration of Helsinki","year":"1989"},{"key":"10.1016\/j.clinthera.2006.01.015_bib22","series-title":"15th Annual Symposium of Pharmaceutical and Biomedical Analysis (PBA)","article-title":"Automated online extraction and tandem mass spectrometry for the analysis of compound I in human plasma [abstract]","author":"Wang","year":"2004"},{"key":"10.1016\/j.clinthera.2006.01.015_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jchromb.2004.03.058","article-title":"High-throughput liquid chromatography for drug analysis in biological fluids: Investigation of extraction column life","volume":"806","author":"Zeng","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2006.01.015_bib24","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2006.01.015_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2307\/1266117","article-title":"The modified GaussNewton method for the fitting of non-linear regression functions by least squares","volume":"3","author":"Hartley","year":"1961","journal-title":"Technometrics"},{"key":"10.1016\/j.clinthera.2006.01.015_bib26","series-title":"Proceedings of the Biopharmaceutical Section, American Statistics Association","first-page":"111","article-title":"Confidence intervals for between-treatment mean difference when analysis is on the log percent scale","author":"Wong","year":"1999"},{"key":"10.1016\/j.clinthera.2006.01.015_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"EurJ Biochem."},{"key":"10.1016\/j.clinthera.2006.01.015_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jc.80.3.952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite invivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.01.015_bib29","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/en.136.8.3585","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and trun cated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.01.015_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diabetes.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2006.01.015_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diabetes.42.5.658","article-title":"Biological effects and metabolic rates of glucagonlike peptide-1 7\u201336 amide and glucagonlike peptide-1 7\u201337 in healthy subjects areindistinguishable","volume":"42","author":"Orskov","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00581038","article-title":"Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7\u201336 amide] in the fasting state in healthy subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2006.01.015_bib34","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7\u201336 amide] after subcutaneous injection in healthy volunteers.Dose-response-relationships","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2006.01.015_bib35","first-page":"A82","article-title":"The DPP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics","volume":"52","author":"Herman","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.01.015_bib36","doi-asserted-by":"crossref","first-page":"R562","DOI":"10.1152\/ajpregu.00599.2003","article-title":"Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men","volume":"287","author":"Gutzwiller","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"10.1016\/j.clinthera.2006.01.015_bib37","doi-asserted-by":"crossref","first-page":"G693","DOI":"10.1152\/ajpgi.00536.2003","article-title":"Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide W, and pancreatic polypeptide","volume":"286","author":"Stanley","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clinthera.2006.01.015_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1389450043490541","article-title":"The pharmacology of human appetite expression","volume":"5","author":"Halford","year":"2004","journal-title":"Curr Drug Targets"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T07:23:31Z","timestamp":1547796211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0149291806000294"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.01.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}